SPRY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. ARS Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Sep. 2024 was $8.81 Mil.
The historical data trend for ARS Pharmaceuticals's Total Long-Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Total Long-Term Assets | 0.02 | 0.72 | 3.74 | 1.46 |
ARS Pharmaceuticals Quarterly Data | ||||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Long-Term Assets | Get a 7-Day Free Trial | 4.09 | 1.46 | 1.34 | 1.23 | 8.81 |
Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.
Thank you for viewing the detailed overview of ARS Pharmaceuticals's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura Shawver | director, officer: Chief Executive Officer | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Eric Karas | officer: Chief Commercial Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Justin Chakma | officer: Chief Business Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Richard E Lowenthal | director, 10 percent owner, officer: President and CEO | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Sarina Tanimoto | 10 percent owner, officer: Chief Medical Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
James E Flynn | director, 10 percent owner, other: Director by deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Kathleen D. Scott | officer: Chief Financial Officer | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Brian Dorsey | officer: Chief Operating Officer | C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Alexander A Fitzpatrick | officer: Chief Legal Officer | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Orbimed Capital Gp Vi Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Rajeev Dadoo | director | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Pratik Shah | director, 10 percent owner | 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037 |
From GuruFocus
By Marketwired • 12-04-2024
By Marketwired • 08-26-2024
By GuruFocus News • 12-05-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 10-24-2024
By Marketwired • 09-23-2024
By GuruFocus Research • 05-13-2024
By Marketwired • 09-10-2024
By Marketwired • 05-09-2024
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.